An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment

Inclusion Criteria

• Participants must have an ECOG performance status of less than or equal to 1
• Participants must have had prior therapy;Participants who have received adjuvant or neoadjuvant anti-PD(L)1 therapy andprogressed within 6 months of completing therapy will be considered IO refractory.
• Participants must have at least 2 lesions with measurable disease as defined by RECIST Version 1.1

Exclusion Criteria

• Participants with suspected, known, or progressive CNS metastases, have untreated CNS metastases, or have the CNS as the only site of disease
• Participants with carcinomatous meningitis
• Participants with other active malignancy requiring concurrent intervention Other protocol defined inclusion/exclusion criteria could apply